Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. The Company is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as Human Immunodeficiency Virus (HIV), Syphilis and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. The Company's manufacturing facilities are located in Halifax, Nova Scotia, Canada.


TSXV:MIR - Post by User

Post by Biofinanaceon Jul 13, 2020 12:07pm
348 Views
Post# 31260769

a lot to adMIRe (Market/FDA/Reiumb)

a lot to adMIRe (Market/FDA/Reiumb)The flood of sero test on the market has created a false expectation of “rapid diagnosis”. FDA is working relentlessly to defunct sero tests (has pulled ~31 Tests from market; de-listed 35 comp in the last few weeks) from comp that failed to estb validation data. So far ~200 sero test kits being distributed in US. Under the recently tightened guidance for serology testing, the FDA set more stringent requirements for performance and is encouraging all serology test providers to submit for emergency use authorization
 
In terms of Reimbursement – CMS released rates for codes 86328 @ $45.23/test (covering point-of-care Qualitative or semi qual tests such as MedMira’s) & 86769 for multi-step lab-based @42.13/test
 
 
Mkt for Sero Test – this is of course oversimplification as mkt is largely unproven given its infancy and could ultimately end up on the larger side if immune protection from the antibodies was not as durable and thus these tests could be required annually – making it a large market longer-term.
 
The market size and price per test will vary across countries but lets say if Medmira gets EUA then largely focus will be in US (given estb CPT codes & FDA stance of estb stringency). Reasons for taking tests mainly being - “Getting workforce back to work” Assay, Identifying recovered patients for convalescent plasma & potential confirmation of vaccine efficacy in the longer term.
 
Using price/test estimate approx. for $45 lateral/vertical flow strip test. We also know that RT-PCR tests are more restricted to symptomatic patients and their close contacts, so there is a huge unpenetrated market that can be exploit using sero test. So, if 20% of Americans get sero testing ~65M people & in order to increase sensitivity/specificity an individual needs to take it twice then market opp comes out to be ~$5.8B. Now, comp that are EUA approved (~25 companies) will take large chunk of this market perhaps 50%-60%  which comes out to be $3.2B. Again this is US market and usually EU is ~1.5-2.5X of what is US.

<< Previous
Bullboard Posts
Next >>